FDMT — 4D Molecular Therapeutics Share News
0.000.00%
Last trade - 00:00- $710.99m
- $369.25m
- $85.21m
Brief: 4D Molecular Therapeutics Q1 Net Income USD -47.972 Million
4D Molecular Therapeutics Inc expected to post a loss of 86 cents a share - Earnings Preview
Brief: 4DMT enrolls first patient in late-stage trial for its retinal eye disease therapy
4D Molecular Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
U.S. RESEARCH ROUNDUP-Applovin, Incyte, Onsemi
BMO downgrades 4D Molecular Therapeutics to 'market perform' on durability concerns
Brief: 4D Molecular Therapeutics Expects Primary Endpoint 52-Week Topline Data For Both 4FRONT-1 And 4FRONT-2 In H2 2027
Brief: 4DMT Reports Positive Interim Data From 4D-150 Spectra Clinical Trial In DME And Alignment With FDA On Registrational Path
U.S. RESEARCH ROUNDUP-Cisco, Freshpet, Nvidia
4D Molecular Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: 4D Molecular Therapeutics Q3 Net Income USD -43.843 Million Vs. IBES Estimate USD -38.4 Million
U.S. RESEARCH ROUNDUP-Athira pharma, Lowe's Companies, P&G
Brief: 4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of Phase 3 Program
4D Molecular Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: 4D Molecular Therapeutics Q2 Net Income USD -34.953 Million Vs. IBES Estimate USD -37.7 Million
4D Molecular Therapeutics Inc expected to post a loss of 70 cents a share - Earnings Preview
Brief: 4DMT Announces FDA Clearance Of IND Application For 4D-175 Genetic Medicine For The Treatment Of Geographic Atrophy
Brief: 4D Molecular Therapeutics Inc says Pursuant To Prospectus Supplement Relating To Offering, Co May Sell Up To $250.0 Million Of Common Stock
Brief: 4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference